What We’re Reading: FDA Reviews ALS Drug; Vaccines Lower Long COVID-19; New COTA President, CEO
March 25th 2022The FDA accepts an application for a drug to treat amyotriphic lateral sclerosis (ALS) for review; vaccines have been found to reduce people’s risk for developing long COVID-19; COTA announces Miruna Sasu, PhD, as its new president and CEO.
Read More
Small Study Finds High Temperatures Worsen Breathing Problems in Patients With COPD
March 24th 2022A recent study found that higher temperatures were associated with worse breathing symptoms and low temperatures were associated with symptoms of bronchitis in participants with chronic obstructive pulmonary disease (COPD).
Read More
Angela Storseth-Cooper Describes PBM Influence in Community Oncology, State-Level Interventions
March 24th 2022Angela Storseth-Cooper, associate director, Government Relations & Public Policy, The US Oncology Network, discusses state-level legislation that community oncology practices can leverage to address issues involving pharmacy benefit managers and the vertical integration of health plans and specialty pharmacies.
Watch
HIIT Shown to Improve Cardiometabolic Risk in Heart Failure
March 24th 2022This study enrolled 80 middle-aged patients with stage A heart failure and evaluated them for improvements in several cardiovascular and metabolic risk factors through high-intensity interval training (HIIT) for 1 year and omega-3 fatty acid supplementation.
Read More
Infliximab Biosimilar Maintains Outcomes, Remission Status After Switch From Originator
March 24th 2022Patients switched from the originator product maintained their clinical outcomes and remissions status while biologic-naïve patients recorded positive responses and remission outcomes after initiating infliximab-dyyb.
Read More
Study Concludes Greater Focus Needed on MAFLD Due to CKD Risk Association
March 24th 2022Investigators confirmed an association between fatty liver disease related to metabolic dysfunction (MAFLD) and chronic kidney disease (CKD), and stressed a greater focus on treating MAFLD is needed to help manage risks.
Read More
MBC Outcomes Superior With Trastuzumab Deruxtecan vs Trastuzumab Emtansine
March 23rd 2022This interim data analysis from the phase 3 DESTINY-Breast03 trial evaluated progression-free survival, overall survival, objective response, and safety between patients with metastatic breast cancer (mBC) progression following previous treatment failure.
Read More
House Dust Mite Sublingual Immunotherapy Shows Promise in Atopic Dermatitis
March 23rd 2022Sublingual immunotherapy with Dermatophagoides pteronyssinus extract was associated with significant improvements in disease severity among patients with atopic dermatitis sensitized to the house dust mite.
Read More